Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


F&P Healthcare shares at highest in over 2 yrs on outlook

F&P Healthcare shares jump to highest in more than 2 years on profit outlook

By Tina Morrison

May 23 (BusinessDesk) - Shares in Fisher & Paykel Healthcare jumped to their highest in more than two years as the maker of breathing masks and respirators said it expects to beat analyst estimates for 2014 profit after surpassing its own guidance for 2013.

F&P Healthcare shares surged 5.9 percent to $3.21, the highest since Feb. 1, 2011, when it touched $3.22. The stock has surged 23 percent so far this year.

Profit is likely to be $85 million to $90 million in the year ending March 13, 2014, managing director Michael Daniell said today. That's more than the $79 million-to-$83 million range expected in a survey of seven analysts by Merlin Consulting.

F&P Healthcare, which competes with Resmed and Respironics, is boosting profit margins on record sales, higher-margin new products and lower costs from its plant in Mexico.

"The share price rise reflects the guidance for 2014 being better than expectations," said Rickey Ward, who manages equities at Tyndall Investment Management. "Next year looks like it's better than forecast."

F&P Healthcare said 2013 profit rose 20 per cent to $77.1 million, ahead of its February guidance of about $75 million. The company boosted operating revenue to a record $556.3 million on strong demand for its respiratory systems and new masks to treat the condition obstructive sleep apnea.

"All of the new products we have invested in over the last 18 months do a better job and in return for that we are getting better margins," Daniell said on a conference call. "We are pretty positive about the coming year."

The company expects operating revenue to rise to between $610 million to $630 million in 2014, Daniell said. The 2014 forecasts are based on the New Zealand dollar trading between 80 US cents and 85 US cents for the remainder of the year as about half its operating revenue is derived in US dollars.

In constant currency terms, which the company uses to show its underlying performance excluding currency affects, operating revenue rose 11 percent. Sales of respiratory products rose 15 percent, while sales of devices to treat obstructive sleep apnea increased 6 per cent.

The annual revenue growth rate in constant currency terms should continue in the mid-teens, driven by new products and applications, Daniell said.

Making an increased quantity and range of products at its plant in Mexico contributed to an improvement in gross margin to 55.3 percent in 2013 from 53.2 percent the year earlier, Daniell said.

Removing the effects of currency volatility, gross margins are expected to expand 100 to 200 basis points a year as a result of new products, efficiencies and the Mexico plant, he said.

F&P Healthcare expects to outlay $40 million in capital expenditure in 2014. That's down from $62 million in 2013 when it spent on new equipment to increase manufacturing capacity, new product tooling, replacement equipment and $33.6 million to complete a third building on its Auckland site.

Research and development spending increased 9 percent in 2013 and current new projects include masks, flow generators, humidifier systems and respiratory and acute care consumables.

It spent 6 percent more on selling as it expanded in North America, Europe and the Asia Pacific regions.

The company's diluted earnings per share increased to 13.8 cents in 2013 from 11.7 cents the year earlier. It will pay a final dividend of 7 cents a share on July 5, unchanged from the year earlier.

(BusinessDesk)

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Statistics: Business Research And Development Up 29 Percent

Computer services and machinery manufacturing firms led the way in an almost 30 percent lift in business spending on research and development (R&D) in 2016, Stats NZ said today. Businesses spent $1.6 billion on R&D in 2016, up $356 million (29 percent) from 2014. More>>

ALSO:

China Shopping: NZ-China FTA Upgrade Agreed Among Slew Of New Deals

New Zealand Prime Minister Bill English and China Premier Li Keqiang signed off a series of cooperation deals spanning trade, customs, travel and climate change and confirmed commencement of official talks on an upgrade to the nine-year old free-trade agreement between the two countries. More>>

ALSO:

Media: TVNZ Flags Job Cuts To Arrest Profit Decline

Chief executive Kevin Kenrick said the changes were aimed at creating "a sustainable future video content business for TVNZ in an ever-changing media market." More>>

ALSO:

Reserve Bank: Wheeler Keeps OCR At 1.75%

Reserve Bank governor Graeme Wheeler kept the official cash rate unchanged at 1.75 percent, as expected, and reiterated his view that the benchmark rate doesn't need shifting for the foreseeable future. More>>

ALSO:

Trade Plans: Prime Minister's Speech To International Business Forum

"The work to improve public services, build infrastructure, and solve social problems is possible only because we have enjoyed sustained, solid economic growth. A big reason for that is the Government’s consistent agenda of economic reform, and our determination to open up more opportunities for trade with the world." More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news